Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldosterone delivery molecule
- Development stage
- Preclinical
- Lead developer
- PIF Partners
- Modality
- Small Molecules
01
Overview
Aldosterone delivery molecule is an investigational, preclinical-stage macrophage-targeting conjugate being developed by PIF Partners. Utilizing the company's proprietary macrophage-targeting platform (the same platform underlying 101-PGC-005), the molecule is designed to selectively deliver aldosterone to CD206+ (activated) macrophages. This targeted approach aims to concentrate the therapeutic effects of aldosterone within inflammatory microenvironments, modulating macrophage activity to treat inflammatory diseases while minimizing systemic exposure and associated side effects.
02
Targets
MRC1 (Mannose Receptor C-type 1)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on aldosterone delivery molecule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldosterone delivery molecule.